cp-55,940 has been researched along with cannabidiol in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, A; Cruciani, G; Fichera, M; Musumarra, G | 1 |
| Fowler, CJ; Lambert, DM | 1 |
| Drmota, T; Elebring, T; Greasley, PJ; Hermansson, NO; Hjorth, S; Larsson, N; Leonova, J; Nilsson, K; Ryberg, E; Sjögren, S | 1 |
| Allen, JG; Babij, P; Fotsch, C | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
| Chung, S; Dangott, LJ; Huang, H; Kier, AB; Landrock, D; Landrock, KK; Li, S; Martin, GG; McIntosh, AL; Schroeder, F | 1 |
| Cheng, J; Duan, W; Hua, T; Li, F; Liu, ZJ; Nie, H; Sun, Y; Wang, H; Wu, M; Xu, Y; Yang, L; Zhang, T; Zhang, Z | 1 |
3 review(s) available for cp-55,940 and cannabidiol
| Article | Year |
|---|---|
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
Topics: Amides; Amidohydrolases; Amines; Animals; Arachidonic Acids; Binding Sites; Cannabinoid Receptor Modulators; Drug Design; Endocannabinoids; Esters; Ethers; Glycerides; Humans; Ligands; Monoacylglycerol Lipases; Polyunsaturated Alkamides; Receptors, Cannabinoid | 2005 |
Emerging targets in osteoporosis disease modification.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Humans; Osteoporosis | 2010 |
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
5 other study(ies) available for cp-55,940 and cannabidiol
| Article | Year |
|---|---|
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
Topics: Arachidonic Acids; Cannabinoids; Drug Design; Endocannabinoids; Indoles; Ligands; Models, Biological; Models, Molecular; Polyunsaturated Alkamides; Receptors, Cannabinoid; Receptors, Drug; Structure-Activity Relationship | 2000 |
The orphan receptor GPR55 is a novel cannabinoid receptor.
Topics: Amino Acid Sequence; Animals; Arachidonic Acids; Binding Sites; Binding, Competitive; Cannabidiol; Cannabinoids; Cell Line; Cloning, Molecular; Cyclohexanols; Down-Regulation; Endocannabinoids; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Mice; Molecular Sequence Data; Organ Specificity; Polymerase Chain Reaction; Polyunsaturated Alkamides; Rats; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Structure-Activity Relationship | 2007 |
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
Topics: Animals; Endocannabinoids; Fatty Acid-Binding Proteins; Female; Fluorescent Dyes; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Receptors, Cannabinoid | 2016 |
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
Topics: Animals; Cannabinoids; Carbon; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Multiple Sclerosis; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Silicon; Structure-Activity Relationship | 2021 |